Clôture précédente | 78,40 |
Ouverture | 77,52 |
Offre | 78,04 x 800 |
Vente | 78,49 x 800 |
Var. jour | 77,28 - 78,40 |
Sur 52 semaines | 57,17 - 89,74 |
Volume | |
Volume moyen | 5 527 200 |
Cap. boursière | 97,443B |
Bêta (mensuel sur 5 ans) | 0,40 |
Rapport P/E (sur 12 mois) | 17,13 |
BPA (sur 12 mois) | S.O. |
Date de bénéfices | S.O. |
Dividende et rendement à terme | 3,00 (3,94 %) |
Date ex-dividende | 14 juin 2023 |
Objectif sur 1 an | S.O. |
NORHAMPTON, MA / ACCESSWIRE / November 10, 2022 / Gilead Sciences While Jesse Garcia was growing up in Chicago's inner city, his parents didn't immediately turn to a doctor when someone in the family got sick. "We relied on traditional Latino ...
NORTHAMPTON, MA / ACCESSWIRE / November 2, 2022 / Gilead Sciences Since the beginning of the COVID-19 pandemic, Gilead's first-in-class antiviral was made available to more than 11 million patients globally- over 65% of whom live in low-and lower-middle-income ...
In the spring of 2018, North Carolina native Stephanie Walker went to her first breast cancer conference and had a revelation that she refers to as her "coming-out party." She learned she had metastatic breast cancer three years earlier and although she was a retired hospice nurse, she faced the disease without any guidance from others who shared her experience.
Gilead Sciences, Inc. (Nasdaq:GILD) recently announced that the Gilead Foundation's Creating Possible Fund™ will provide a total of $20 million to 13 inaugural grantees. The Creating Possible Fund was launched to support creative and high-impact strategies that advance health through education equity, with a main focus on building a pipeline of Black health leaders.